Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2012 1
2014 1
2015 1
2018 1
2019 3
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Cohen SB, et al. Among authors: enejosa jv. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Ann Rheum Dis. 2021. PMID: 33115760 Free PMC article. Clinical Trial.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH. Fleischmann RM, et al. Among authors: enejosa jv. Ann Rheum Dis. 2019 Nov;78(11):1454-1462. doi: 10.1136/annrheumdis-2019-215764. Epub 2019 Jul 30. Ann Rheum Dis. 2019. PMID: 31362993 Free PMC article. Clinical Trial.
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V, Paduta D, Viani RM, Enejosa JV, Pasechnikov V, Znoyko O, Ogurtsov P, Bogomolov PO, Maevskaya MV, Chen X, Shulman NS. Isakov V, et al. Among authors: enejosa jv. Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1073-1076. doi: 10.1097/MEG.0000000000001166. Eur J Gastroenterol Hepatol. 2018. PMID: 29762255 Clinical Trial.
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y, Chen S, Song IH. Peterfy CG, et al. Among authors: enejosa jv. Rheumatology (Oxford). 2022 Aug 3;61(8):3246-3256. doi: 10.1093/rheumatology/keab861. Rheumatology (Oxford). 2022. PMID: 34897366 Free PMC article. Clinical Trial.
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y. Schanberg LE, et al. Among authors: enejosa jv. Arthritis Rheumatol. 2019 Dec;71(12):1976-1984. doi: 10.1002/art.41043. Epub 2019 Nov 1. Arthritis Rheumatol. 2019. PMID: 31313532
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L Jr, Hu YB, Podsadecki T, Bernstein B. Andreone P, et al. Among authors: enejosa jv. Gastroenterology. 2014 Aug;147(2):359-365.e1. doi: 10.1053/j.gastro.2014.04.045. Epub 2014 May 9. Gastroenterology. 2014. PMID: 24818763 Free article. Clinical Trial.
12 results